Antipsychotic effects on cognition in schizophrenia: A meta-analysis of randomised controlled trials

European Journal of Psychiatry

Volumn 23, Issue 2, 2009, Pages 77-89

  Guilera, Georgina ^a   Pino, Oscar ^b   Gómez Benito, Juana ^a   Rojo, J Emilio ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL GENERAL DE GRANOLLERS   (Spain)

Author keywords

Antipsychotic agents; Meta analysis; Randomised controlled trials; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ALERTNESS; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITION; COMPREHENSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUSTRY; EFFECT SIZE; HUMAN; INTELLIGENCE; LEARNING; META ANALYSIS; NEUROPSYCHOLOGICAL TEST; PERCEPTION; PROBLEM SOLVING; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SYSTEMATIC REVIEW; TREATMENT DURATION; WORKING MEMORY;

EID: 77955371717     PISSN: 02136163     EISSN: None     Source Type: Journal    
DOI: 10.4321/S0213-61632009000200002     Document Type: Article

References (50)

1. Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomised, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161: 985-995.
2. Harvey PD, Sharma T. Understanding and treating cognition in schizophrenia: A clinician's handbook. London, UK: Martin Dunitz; 2002.
3. Green MF, Kern RS, Heaton PK. Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS. Schizophr Res 2004; 72: 41-51.
4. Green MF, Olivier B, Crawley JN, Penn DL, Silverstein S. Social cognition in schizophrenia: Recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizoph Bull 2005; 31: 882-887.
5. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-330.
6. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000; 45: 175-184.
7. Sergi MJ, Kern RS, Mintz J, Green MF. Learning potential and the prediction of work skill acquisition in schizophrenia. Schizophr Bull 2005; 31: 67-72.
8. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36: 717-725.
9. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76: 1521-1531.
10. Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: Role of 5-HT1A receptor agonism. Brain Res 2002; 956: 349-357.
11. st edition. Barcelona: Fundació SENY; 2004.
12. Noguer-Carmona S, Gallo P, Parada A, García-Duran Huet M, Méndez-Vásquez RI, Suñén-Pinyol E. Estudio bibliométrico sobre esquizofrenia en España (1999-2004): productividad, impacto y colaboración, 2nd edition. Barcelona: Fundació SENY; 2006.
13. Harvey PD, Siu CO, Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology 2004; 172: 324-332.
14. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: A comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005; 162: 1888-1895.
15. Harvey PD, Keefe RSE. Interpreting studies of cognitive change in schizophrenia with novel antipsychotic treatment. Am J Psychiatry 2001; 158: 176-184.
16. Keefe RSE, Silva SM, Perkins S, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and metaanalysis. Schizophr Bull 1999; 25: 201-222.
17. Green MF, Nuechterlein KH. The MATRICS initiative: Developing a consensus cognitive battery for clinical trials. Schizophr Res 2004; 72: 1-3.
18. Kern RS, Green MF, Nuechterlein KH, Deng BH. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res 2004; 72: 11-19.
19. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004; 72: 29-39.
20. rd edition. New York: Oxford University Press; 2004.
21. Carpenter WT, Gold JM. Another view of therapy for cognition in schizophrenia. Biol Psychiatry 2002; 51: 969-971.
22. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 8: 457-472.
23. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007; 64: 633-647.
24. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564.
25. Serretti A, De Ronchi D, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: A review on efficacy and side effects. Cur Medicinal Chemistry 2004; 11: 343-358.
26. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects. Schizophr Res 2007; 89: 211-224.
27. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
28. Hedges LV. Distribution theory for Glass' estimator of effect size and related estimators. J Educational Statistics 1981; 6: 197-228.
29. Cohen J. Power analysis for the behavioral sciences. Hillsdale: Lawrence Erlbaum Associates; 1988.
30. Hedges LV, Olkin I. Statistical methods for metaanalysis. New York: Academic Press; 1985.
31. Borenstein M, Rothstein H. Comprehensive Meta-Analysis: A computer program for research synthesis. Englewood, NJ: Biostat; 1999.
32. Rosenthal R. The "file drawer problem" and tolerance for null results. Psychol Bull 1979; 86: 638-641.
33. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 1018-1028.
34. Fagerlund B, Mackeprang T, Gade A, GlenthΔj BY. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drugnaive schizophrenic patients. CNS Spectr 2004; 9: 364-374.
35. Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 2006; 59: 97-105.
36. Kern RS, Green MF, Marshall BD Jr,Wirshing WC, Wirshing D, McGurk SR, et al. Risperidone versus haloperidol on secondary memory: Can newer medications aid?. Schizophr Bull 1999; 25: 223-232.
37. Lee MA, Javathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res 1999; 37: 1-11.
38. Lee SM, Chou YH, Li MH, Wan FJ, Yen MH. Effects of antipsychotics on cognitive performance in drugnaive schizophrenic patients. Prog Neuro-Psychopharmacol Biol Psychiatry 2007; 31: 1101-1107.
39. Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B. A randomized controlled trial of olanzapine varsus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 2007; 68: 368-379.
40. Liu SK, Chen WJ, Chang CJ, Lin HN. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: A trial of risperidone versus haloperidol. Neuropsychopharmacology 2000; 22: 311-319.
41. Ljubin T, Zakic Milas D, Mimica N, Folnegovic-Smalc V, Makaric G. A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients. Hum Psychopharmacol 2000; 15: 513-519.
42. McGurk SR, Green MF, Wirshing WC, Wirshing DA, Marder SR, Mintz J, Kern R. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr Res 2004; 68: 225-233.
43. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000; 57: 249-258.
44. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001; 26: 137-149.
45. Purdon SE, Woodward N, Lindborg SR, Stip E. Procedural learning in schizophrenia after 6 months of doubleblind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology 2003; 169: 390-397.
46. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, et al. Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophr Res 2002; 53: 239-248.
47. Kasper S, Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 2003; 28: 27-38.
48. rd ed. San Antonio, Texas: Psychological Corporation; 1997.
49. rd ed. San Antonio, Texas: Psychological Corporation; 1997.
50. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004; 55: 1013-1022.